US Launch

Fulcrum Pharma PLC
24 June 2002


For Immediate Release:                           07.00, Monday 24th June 2002



                        FULCRUM PHARMA DEVELOPMENTS LTD

                         US Launch:  New Office Opened
                                       &
            Appointment of CEO for Fulcrum Pharma Developments, Inc.


Hemel Hempstead, UK - Fulcrum Pharma plc (LSE: FUL), the independent drug
development company, announced today the establishment of its U.S. subsidiary,
Fulcrum Pharmaceutical Developments, Inc.   It also announced  the appointment
of Dr. Bruce McCreedy, previously with Triangle Pharmaceuticals, as Chief
Executive Officer of the new company.  This first US office will be located in
Research Triangle Park, North Carolina and it will also act as the Group's U.S.
headquarters going forward.  It is envisaged that other subsidiary offices will
be opened in due course in biotechnology centers across the country to support
Fulcrum's U.S. expansion programme.

The establishment of the U.S. subsidiary will enable Fulcrum to provide
dedicated services for existing clients who have operations in North America as
well as to aggressively pursue new business opportunities with potential
customers based both in the U.S. and Canada.  The addition of Fulcrum
Pharmaceutical Developments, Inc. to the existing Fulcrum operations in the U.K.
and Japan significantly enhances the global  capabilities that Fulcrum is able
to provide to its customers.

In assuming the role of CEO of Fulcrum Pharmaceutical Developments, Inc., Dr.
McCreedy brings more than fifteen years of experience in drug development,
executive management, and business operations.  Dr. McCreedy has extensive
training and experience in infectious diseases and development of
anti-infectives and is internationally recognized as an expert in the field of
therapeutic monitoring and drug resistance.

Previously, Dr. McCreedy held positions as Associate Vice President of
Infectious Diseases and Clinical Trials with Roche Biomedical Laboratories (now
Laboratory Corporation of America), Vice President of Clinical Virology and
Diagnostics with Triangle Pharmaceuticals, and most recently as CEO of
TherapyEdge, Inc., a company that Dr. McCreedy co-founded as a spin off of
Triangle Pharmaceuticals.  Dr. McCreedy received his undergraduate degree in
Medical Microbiology from Wake Forest University and a Ph.D. in Microbiology,
Immunology, and Molecular Biology from Wake Forest University School of
Medicine.

Dr Jon Court, Fulcrum's Chief Executive Officer, welcomed this new initiative
saying:

'We are delighted that Dr McCreedy has joined Fulcrum and that he will establish
our first office in North Carolina. This office will enable Fulcrum to provide
local support to its US customers and offer its clients full global services. We
look forward to Dr. McCreedy's complimentary drug development and business
experience adding further strength and depth to the existing management team.

'Development of a presence in the US is a key element of the Company's expansion
programme and I look forward to updating you on our progress in this area.'

Dr Bruce McCreedy also welcomed this development, saying:

'I'm very excited to be joining the experienced team of professionals at
Fulcrum.  The virtual drug development model and processes employed by Fulcrum
have proven their value in decreasing the time and costs of drug development.
The establishment of the U.S. subsidiary and the addition of talented and
experienced staff to the existing team will allow Fulcrum to provide the
benefits of its product offering with dedicated services for pharmaceutical and
biotechnology companies with operations in North America.'



                                    - ENDS -



For further information, please contact :

Fulcrum Pharma plc
Jon Court, Chief Executive                                  0870 710 7152
Neil Oughton, Company Secretary                             0870 710 7155
www.fulcrumpharma.com

Buchanan Communication
Nicola How / Louise Bolton                                   0207 466 5000



Notes to Editors:

Fulcrum Pharma plc is an independent, strategic, drug development services
company that aims to be the pharmaceutical industry's first choice for optimal
management of drug development.

Fulcrum offers a unique strategic drug development service to the pharmaceutical
and biotechnology industries. The company provides customized development
programmes that lead to early Proof of Concept, efficient registration and ideal
positioning for rapid availability to patients. Fulcrum's service is
professional and cost-effective.

Fulcrum's experienced senior managers personally oversee drug development
projects via an advanced management process, combining exceptional project
leadership and problem solving skills with an external team of specifically
selected suppliers and independent experts to meet the needs of our clients.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange.



                      This information is provided by RNS
            The company news service from the London Stock Exchange